Highly active anti-retroviral therapy (HAART) has proved very successful in reducing the morbidity and mortality associated with HIV infection. This same lifespan prolongation, however, has also revealed many side effects linked to HAART, including cardiovascular disease. A once daily fixed dose drug combination pill Atripla was hoped to improve compliance and adherence. The HAART components of Atripla efavirenz, emtricitabine and tenofovir are considered to be significantly safer than the conventional reverse transcriptase inhibitors but cardiovascular effects of these drugs have yet to be investigated in vitro. The overall objective of this thesis was to examine the effects of the three components of Atripla on cardiovascular cell function.
|Date of Award||2013|